<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">291</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2019-18-4-99-104</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SCHOOL OF IMMUNOLOGY – EXPERT OPINION</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ШКОЛА ИММУНОЛОГА – МНЕНИЕ ЭКСПЕРТА</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Granulomatous inflammation in the manifestation of chronic granulomatous disease: a clinical case report</article-title><trans-title-group xml:lang="ru"><trans-title>Гранулематозное воспаление в манифестации хронической гранулематозной болезни: клинический случай</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9078-8206</contrib-id><name-alternatives><name xml:lang="en"><surname>Yukhacheva</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Юхачева</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p/><p><bold>Correspondence:</bold> Daria V. Yukhacheva, MD, Department of Clinical Immunology of Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation.</p><italic>Address: Russia 117997, Moscow, Samory Mashela st., 1</italic></bio><bio xml:lang="ru"><p/><p><bold>Контактная информация</bold>: Юхачева Дарья Валерьевна, врач – аллерголог-иммунолог отделения иммунологии НМИЦ детской гема- тологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России.</p><italic>Адрес: 117997, Москва, ГСП-7, ул. Саморы Машела, 1</italic></bio><email>yukhachevadv@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6148-7209</contrib-id><name-alternatives><name xml:lang="en"><surname>Pershin</surname><given-names>D. E.</given-names></name><name xml:lang="ru"><surname>Першин</surname><given-names>Д. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9424-1646</contrib-id><name-alternatives><name xml:lang="en"><surname>Uskova</surname><given-names>N. G.</given-names></name><name xml:lang="ru"><surname>Ускова</surname><given-names>Н. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7317-7104</contrib-id><name-alternatives><name xml:lang="en"><surname>Tereshchenko</surname><given-names>G. V.</given-names></name><name xml:lang="ru"><surname>Терещенко</surname><given-names>Г. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1669-8621</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuzmenko</surname><given-names>N. B.</given-names></name><name xml:lang="ru"><surname>Кузьменко</surname><given-names>Н. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>Moscow</italic></p></bio><bio xml:lang="ru"><p><italic>Москва</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-12-31" publication-format="electronic"><day>31</day><month>12</month><year>2019</year></pub-date><volume>18</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>99</fpage><lpage>104</lpage><history><date date-type="received" iso-8601-date="2019-12-31"><day>31</day><month>12</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-12-31"><day>31</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/291">https://hemoncim.com/jour/article/view/291</self-uri><abstract xml:lang="en"><p>Chronic granulomatous disease is a primary immunodeficiency, characterized by a violation of the oxygen-dependent mechanisms of phagocytosis. Mutations in the genes encoding proteins of the NADPH-oxidase complex lead to a violation of the respiratory burst. Clinical manifestations are recurrent bacterial and fungal infections, and the development of granulomatous complications due to a defect in autophagy, accompanied by an increase in the level of interleukin-1 inthe blood. The treatment of this disease is continuous preventive antimicrobial therapy, and specific therapy for the treatment of granulomatous complications. Hematopoietic stem cell transplantation from an allogeneic or unrelated donor is currently considered to be only radical treatment for CGD. This article presents a clinical case of the manifestation of an X-linked form of chronic granulomatous disease with granulomatous manifestations in the absence of an infectious history. Parents patient agreed to use personal data in research and publications.</p></abstract><trans-abstract xml:lang="ru"><p>Хроническая гранулематозная болезнь – первичный иммунодефицит, характеризующийся нарушением кислородозависимых механизмов фагоцитоза, так как при мутациях в генах, кодирующих белки НАДФН-оксидазного комплекса, происходит нарушение респираторного взрыва. Клинические проявления этой болезни – рецидивирующие бактериальные и грибковые инфекции, а также развитие гранулематозных осложнений вследствие дефекта аутофагии, сопровождающееся повышением уровня интерлейкина-1 в крови. Лечение данного заболевания заключается в постоянной профилактической противомикробной терапии, а также специфической терапии для лечения гранулематозных осложнений. При этом единственным радикальным методом лечения этого заболевания считается трансплантация гемопоэтических стволовых клеток от аллогенного родственного или неродственного донора. В статье представлен клинический случай манифестации Х-сцепленной формы хронической гранулематозной болезни с гранулематозных проявлений при отсутствии инфекционного анамнеза. Родители дали согласие на использование информациио ребенке в научных исследованиях и публикациях.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic granulomatous disease</kwd><kwd>СGD</kwd><kwd>CYBB</kwd><kwd>NADPH - oxidase complex</kwd><kwd>respiratory burst</kwd><kwd>rhodamine test</kwd><kwd>granulomatous inflammation</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая гранулематозная болезнь</kwd><kwd>ХГБ</kwd><kwd>CYBB</kwd><kwd>НАДФН-оксидазный комплекс</kwd><kwd>респираторный взрыв</kwd><kwd>тест с родамином</kwd><kwd>гранулематозное воспаление</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Janeway C.A., Craig J., Davidson M., Downey W., Gitlin D., Sullivan J.C. Hypergammaglobulinemia associated with severe, recurrent and chronic non-specific infection. Am J Dis Child 1954; 88: 388–92.</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2.	Bridges R.A., Berendes H., Good R.A. A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome. AMA J Dis Child 1959; 97: 387–408.</mixed-citation><mixed-citation xml:lang="ru">Bridges R.A., Berendes H., Good R.A. A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome. AMA J Dis Child 1959; 97: 387–408.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3.	Landing B.H., Shirkey H.S. A syndrome of recurrent infection and infiltration of viscera by pigmented lipid histiocytes. Pediatrics 1957; 20: 431–8.</mixed-citation><mixed-citation xml:lang="ru">Landing B.H., Shirkey H.S. A syndrome of recurrent infection and infiltration of viscera by pigmented lipid histiocytes. Pediatrics 1957; 20: 431–8.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4.	Seger R.A. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 2010; 68 (11): 334–40.</mixed-citation><mixed-citation xml:lang="ru">Seger R.A. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 2010; 68 (11): 334–40.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5.	Rider N.L., Jameson M.B., Creech C.B. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc 2018; 7: S2–S5.</mixed-citation><mixed-citation xml:lang="ru">Rider N.L., Jameson M.B., Creech C.B. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc 2018; 7: S2–S5.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6.	Segal B.H., Leto T.L., Gallin J.I., Malech H.L., Holland S.M. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine 2000; 79: 170–200.</mixed-citation><mixed-citation xml:lang="ru">Segal B.H., Leto T.L., Gallin J.I., Malech H.L., Holland S.M. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine 2000; 79: 170–200.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7.	Harrison R.E., Touret N., Grinstein S. Microbial killing: oxidants, proteases and ions. Curr Biol 2002; 12: 357–9.</mixed-citation><mixed-citation xml:lang="ru">Harrison R.E., Touret N., Grinstein S. Microbial killing: oxidants, proteases and ions. Curr Biol 2002; 12: 357–9.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8.	Fang F.C. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004; 2: 820–32.</mixed-citation><mixed-citation xml:lang="ru">Fang F.C. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004; 2: 820–32.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9.	Meischl C., Roos D. The molecular basis of chronic granulomatous disease. Springer Semin Immunopathol. 1998; 19: 417–34.</mixed-citation><mixed-citation xml:lang="ru">Meischl C., Roos D. The molecular basis of chronic granulomatous disease. Springer Semin Immunopathol. 1998; 19: 417–34.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10.	Jennifer W.L., Steven M.H. Chronic granulomatous disease. Seattle (WA): University of Washington, Seattle; 1993–2019. Initial Posting: 09.082012; Last Update: 11.02.2016.</mixed-citation><mixed-citation xml:lang="ru">Jennifer W.L., Steven M.H. Chronic granulomatous disease. Seattle (WA): University of Washington, Seattle; 1993–2019. Initial Posting: 09.082012; Last Update: 11.02.2016.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11.	Segal A.W. The NADPH oxidase and chronic granulomatous disease. Mol Med Today 1996; 2 (3): 129–35.</mixed-citation><mixed-citation xml:lang="ru">Segal A.W. The NADPH oxidase and chronic granulomatous disease. Mol Med Today 1996; 2 (3): 129–35.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12.	Rieber N., Hector A., Kuijpers T., Roos D., Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol 2012; Article ID 252460. Published online 25.07.2011.</mixed-citation><mixed-citation xml:lang="ru">Rieber N., Hector A., Kuijpers T., Roos D., Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol 2012; Article ID 252460. Published online 25.07.2011.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13.	Allen R.C., Stjernholm R.L., Reed M.A., Harper T.B., Gupta S., Steele R.H., Waring W.W. Correlation of metabolic and chemiluminescent responses of granulocytres from three female siblings with chronic granulomatous disease. J Infect Dis 136: 510–8.</mixed-citation><mixed-citation xml:lang="ru">Allen R.C., Stjernholm R.L., Reed M.A., Harper T.B., Gupta S., Steele R.H., Waring W.W. Correlation of metabolic and chemiluminescent responses of granulocytres from three female siblings with chronic granulomatous disease. J Infect Dis 136: 510–8.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14.	Emmendörffer A., Hecht M., LohmannMatthes M.L., Roesler J. A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123. J Immunol Methods 1990; 131 (2): 269–75.</mixed-citation><mixed-citation xml:lang="ru">Emmendörffer A., Hecht M., LohmannMatthes M.L., Roesler J. A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123. J Immunol Methods 1990; 131 (2): 269–75.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15.	Slack M.A., Thomsen I.P. Prevention of infectious complications in patients with chronic granulomatous disease. J Pediatric Infect Dis Soc 2018; 7: S25–S30.</mixed-citation><mixed-citation xml:lang="ru">Slack M.A., Thomsen I.P. Prevention of infectious complications in patients with chronic granulomatous disease. J Pediatric Infect Dis Soc 2018; 7: S25–S30.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16.	Henrickson S.E., Jongco A.M., Thomsen K.F., Garabedian E.K, Thomsen I.P. Noninfectious Manifestations and Complications of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc 2018; 7: S18–S24.</mixed-citation><mixed-citation xml:lang="ru">Henrickson S.E., Jongco A.M., Thomsen K.F., Garabedian E.K, Thomsen I.P. Noninfectious Manifestations and Complications of Chronic Granulomatous Disease. J Pediatric Infect Dis Soc 2018; 7: S18–S24.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17.	Kobayashi S., Murayama S., Takanashi S., Miyatsuka S., Fujita T., Ichinohe S., et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatrics 2008; 167 (12): 1389–94.</mixed-citation><mixed-citation xml:lang="ru">Kobayashi S., Murayama S., Takanashi S., Miyatsuka S., Fujita T., Ichinohe S., et al. Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan. Eur J Pediatrics 2008; 167 (12): 1389–94.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18.	Vinh D.C., Freeman A.F., Shea Y.R., Malech H.L., Abinun M., Weinberg G.A., Holland S.M. Mucormycosis in chronic granulomatous disease: association with iatrogenic immunosuppression. J Allergy Clin Immunol 2009; 123 (6): 1411–3.</mixed-citation><mixed-citation xml:lang="ru">Vinh D.C., Freeman A.F., Shea Y.R., Malech H.L., Abinun M., Weinberg G.A., Holland S.M. Mucormycosis in chronic granulomatous disease: association with iatrogenic immunosuppression. J Allergy Clin Immunol 2009; 123 (6): 1411–3.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19.	Uzel G., Orange J.S., Poliak N., Marciano B.E., Heller T., Holland S.M. Complications of tumor necrosis factor- blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010; 15; 51 (12): 1429–34.</mixed-citation><mixed-citation xml:lang="ru">Uzel G., Orange J.S., Poliak N., Marciano B.E., Heller T., Holland S.M. Complications of tumor necrosis factor- blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010; 15; 51 (12): 1429–34.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20.	van de Veerdonk F.L., Dinarello C.A. Deficient autophagy unravels the ROS paradox in chronic granulomatous disease. Autophagy 2014; 10 (6): 1141–2.</mixed-citation><mixed-citation xml:lang="ru">van de Veerdonk F.L., Dinarello C.A. Deficient autophagy unravels the ROS paradox in chronic granulomatous disease. Autophagy 2014; 10 (6): 1141–2.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21.	Seger R.A. Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol Allergy Clin North Am 2010; 30 (2): 195–208.</mixed-citation><mixed-citation xml:lang="ru">Seger R.A. Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol Allergy Clin North Am 2010; 30 (2): 195–208.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22.	Kuhns D.B., Alvord W.G., Heller T., Feld J.J., Pike K.M., Marciano B.E., et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363 (27): 2600–10.</mixed-citation><mixed-citation xml:lang="ru">Kuhns D.B., Alvord W.G., Heller T., Feld J.J., Pike K.M., Marciano B.E., et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363 (27): 2600–10.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23.	Мухина А.А., Кузьменко Н.Б., Родина Ю.А., Кондратенко И.В., Бологов А.А., Латышева Т.В. и др. Характеристика пациентов с первичными иммунодефицитными состояниями в Российской Федерации: от рождения до старости. Педиатрия 2019; 98 (3): 24–31.</mixed-citation><mixed-citation xml:lang="ru">Мухина А.А., Кузьменко Н.Б., Родина Ю.А., Кондратенко И.В., Бологов А.А., Латышева Т.В. и др. Характеристика пациентов с первичными иммунодефицитными состояниями в Российской Федерации: от рождения до старости. Педиатрия 2019; 98 (3): 24–31.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24.	Meissner F., Seger R.A., Moshous D., Fischer A., Reichenbach J., Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease Blood 2010; 116 (9): 1570–3.</mixed-citation><mixed-citation xml:lang="ru">Meissner F., Seger R.A., Moshous D., Fischer A., Reichenbach J., Zychlinsky A. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease Blood 2010; 116 (9): 1570–3.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. de Luca A., Smeekens S.P., Casagrande A., Iannitti R., Conway K.L., Gresnigt M.S., et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci USA 2014; 111(9): 3526–31.</mixed-citation><mixed-citation xml:lang="ru">de Luca A., Smeekens S.P., Casagrande A., Iannitti R., Conway K.L., Gresnigt M.S., et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci USA 2014; 111(9): 3526–31.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
